These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17403430)

  • 1. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.
    Page JG; Tian B; Schweikart K; Tomaszewski J; Harris R; Broadt T; Polley-Nelson J; Noker PE; Wang M; Makhija S; Aurigemma R; Curiel DT; Alvarez RD
    Am J Obstet Gynecol; 2007 Apr; 196(4):389.e1-9; discussion 389.e9-10. PubMed ID: 17403430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
    Kim KH; Ryan MJ; Estep JE; Miniard BM; Rudge TL; Peggins JO; Broadt TL; Wang M; Preuss MA; Siegal GP; Hemminki A; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
    Hum Gene Ther; 2011 Jul; 22(7):821-8. PubMed ID: 21171861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.
    Kim KH; Dmitriev IP; Saddekni S; Kashentseva EA; Harris RD; Aurigemma R; Bae S; Singh KP; Siegal GP; Curiel DT; Alvarez RD
    Gynecol Oncol; 2013 Sep; 130(3):518-24. PubMed ID: 23756180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
    Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
    Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer.
    Matthews K; Noker PE; Tian B; Grimes SD; Fulton R; Schweikart K; Harris R; Aurigemma R; Wang M; Barnes MN; Siegal GP; Hemminki A; Zinn K; Curiel DT; Alvarez RD
    Clin Cancer Res; 2009 Jun; 15(12):4131-7. PubMed ID: 19509153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.
    Kimball KJ; Preuss MA; Barnes MN; Wang M; Siegal GP; Wan W; Kuo H; Saddekni S; Stockard CR; Grizzle WE; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
    Clin Cancer Res; 2010 Nov; 16(21):5277-87. PubMed ID: 20978148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
    Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
    Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy.
    Rocconi RP; Numnum MT; Zhu ZB; Lu B; Wang M; Rivera AA; Stoff-Khalili M; Alvarez RD; Curiel DT; Makhija S
    Gynecol Oncol; 2006 Dec; 103(3):985-9. PubMed ID: 16857247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer.
    Kim KH; Dmitriev I; O'Malley JP; Wang M; Saddekni S; You Z; Preuss MA; Harris RD; Aurigemma R; Siegal GP; Zinn KR; Curiel DT; Alvarez RD
    Clin Cancer Res; 2012 Jun; 18(12):3440-51. PubMed ID: 22510347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Kirby TO; Rivera A; Rein D; Wang M; Ulasov I; Breidenbach M; Kataram M; Contreras JL; Krumdieck C; Yamamoto M; Rots MG; Haisma HJ; Alvarez RD; Mahasreshti PJ; Curiel DT
    Clin Cancer Res; 2004 Dec; 10(24):8697-703. PubMed ID: 15623655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy.
    Wu H; Han T; Lam JT; Leath CA; Dmitriev I; Kashentseva E; Barnes MN; Alvarez RD; Curiel DT
    Gene Ther; 2004 May; 11(10):874-8. PubMed ID: 14999229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas.
    Yong RL; Shinojima N; Fueyo J; Gumin J; Vecil GG; Marini FC; Bogler O; Andreeff M; Lang FF
    Cancer Res; 2009 Dec; 69(23):8932-40. PubMed ID: 19920199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
    Lam JT; Kanerva A; Bauerschmitz GJ; Takayama K; Suzuki K; Yamamoto M; Bhoola SM; Liu B; Wang M; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
    J Gene Med; 2004 Dec; 6(12):1333-42. PubMed ID: 15493039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic replacement of the adenovirus shaft fiber reduces liver tropism in ovarian cancer gene therapy.
    Breidenbach M; Rein DT; Wang M; Nettelbeck DM; Hemminki A; Ulasov I; Rivera AR; Everts M; Alvarez RD; Douglas JT; Curiel DT
    Hum Gene Ther; 2004 May; 15(5):509-18. PubMed ID: 15144580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
    Raki M; Kanerva A; Ristimaki A; Desmond RA; Chen DT; Ranki T; Sarkioja M; Kangasniemi L; Hemminki A
    Gene Ther; 2005 Aug; 12(15):1198-205. PubMed ID: 15800658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.
    Kanerva A; Wang M; Bauerschmitz GJ; Lam JT; Desmond RA; Bhoola SM; Barnes MN; Alvarez RD; Siegal GP; Curiel DT; Hemminki A
    Mol Ther; 2002 Jun; 5(6):695-704. PubMed ID: 12027553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.
    Paielli DL; Wing MS; Rogulski KR; Gilbert JD; Kolozsvary A; Kim JH; Hughes J; Schnell M; Thompson T; Freytag SO
    Mol Ther; 2000 Mar; 1(3):263-74. PubMed ID: 10933942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
    de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
    J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.